Pulmonary Fibrosis

Among patients with progressive pulmonary fibrosis, taking nintedanib for 52 weeks lowered the degree of worsened dyspnea, fatigue and cough compared with placebo, according to results published in European Respiratory Journal.

Patients with pulmonary fibrosis who used a smartphone app that offers cognitive behavioral therapy showed improvements in anxiety levels and quality of life, according to a press release.

In patients with pulmonary fibrosis, consuming omega-3 fatty acids may improve diffusing capacity for carbon monoxide and lengthen survival, according to results published in CHEST.

Over time, adults with severe obstructive sleep apnea had more high attenuation areas on CT and lower lung function, which may signal early interstitial lung disease, according to data published in Annals of the American Thoracic Society.

Patients with interstitial lung disease and surfactant-related gene mutations showed progressive lung function decline and reduced survival that was comparable to that of other ILD groups, according to results published in CHEST.

The FDA granted breakthrough therapy designation to an oral lysophosphatidic acid receptor 1 antagonist that lowered the rate of percent-predicted FVC decline among patients with progressive pulmonary fibrosis.

HONOLULU — Risk for mortality and hospitalization did not differ between patients with idiopathic pulmonary fibrosis taking 100 mg or 150 mg nintedanib twice daily, according to a real-world analysis presented at the CHEST Annual Meeting.

Receiving an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks lowered the rate of percent predicted FVC decline in progressive pulmonary fibrosis, according to a European Respiratory Society International Congress presentation.

Given the rarity of pulmonary fibrosis, pulmonologists are constantly seeking to know more about the disease and advance research on treatment options.

Patients with COVID-19-related acute respiratory distress syndrome undergoing transplantation had comparable, high survival rates to patients with COVID-19-related pulmonary fibrosis, according to results published in JAMA Surgery.